Download PDF
CC BY 4.0 · Arch Plast Surg 2024; 51(04): 372-377
DOI: 10.1055/a-2306-0962
Pediatric/Craniomaxillofacial/Head & Neck
Idea and Innovation

A Triple Laser Combination Treatment for Facial Angiofibromata Management in Tuberous Sclerosis and Literature Review

F. Neamonitou 
1   Department of Plastic Surgery, General Anticancer Oncological Hospital of Athens ‘Saint Savvas’, Athens, Greece
,
K.K. Neamonitos 
2   Department of Dermatology, General University Hospital of Athens ‘Attikon’, Athens, Greece
,
S. Stavrianos 
1   Department of Plastic Surgery, General Anticancer Oncological Hospital of Athens ‘Saint Savvas’, Athens, Greece
,
K.P. Neamonitos 
3   Hellenic Society of Dermatology Surgery (HSDS), Private Dermatological Clinic ‘Laserderm Academy’, Athens, Greece
› Author Affiliations Funding None.
› Further Information
   Permissions and Reprints

Abstract

Angiofibromas are a common facial manifestation of tuberous sclerosis (TS). However, current treatments have proven ineffective due to high recurrence rates and noncompliance. To address this issue, we developed a new triple laser therapy protocol for more effective management of angiofibromas. We conducted tests to validate its efficacy. This is a prospective study of 10 patients with TS (4 women and 6 men, mean age 26.3 years [15–37 years]) with angiofibromata who received triple sequential laser therapy at our private dermatological clinic conducted from January 2000 to December 2022. We evaluated the outcome with the Facial Angiofibromata Severity Index (FASI) via clinical photography (0, 6 months, 1 year, and 2 years), and Dermatology Life Quality Index (DLQI). All patients had a successful recovery without any complications. Among these 10 patients, 4 experienced localized recurrences at their 6-month follow-up. These recurrences were treated with a second single carbon dioxide laser session. After 2 years of follow-up, we observed no recurring facial cutaneous manifestations. Furthermore, all patients experienced a decrease in their FASI score after treatment. According to the Visual Analogue Scale, patients reported 95% satisfaction, and DLQI indicated only a minor impact on their everyday lives. We believe that this protocol of three-step laser treatment is effective, safe, and compliable for patients with facial angiofibromata, providing a satisfactory outcome adaptable to the daily dermatological and plastic surgery practice.

Keywords

angiofibroma - Erbium - laser - pulsed dye laser - tuberous sclerosis

Authors' Contributions

Conceptualization: F.N., K.P.N., Data curation: F.N., K.K.N. Formal analysis: F.N., K.K.N. Methodology: F.N. Project administration: K.P.N. Writing - original draft: F.N., K.K.N. Writing - review & editing: F.N., K.P.N., S.S.


Ethical Approval

The study was approved by the Institutional Review Board of the Dermatological Clinic Laserderm Academy and performed in accordance with the principles of the Declaration of Helsinki. Written informed consents were obtained.


Patient Consent

Before treatment, we obtained informed consent from all patients or their guardians in case the patients could not obtain consent.




Publication History

Received: 20 July 2023

Accepted: 09 April 2024

Accepted Manuscript online:
15 April 2024

Article published online:
14 June 2024

© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Leung AK, Robson WL. Tuberous sclerosis complex: a review. J Pediatr Health Care 2007; 21 (02) 108-114
    CrossrefPubMedGoogle Scholar
  • 2 Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. N Engl J Med 2006; 355 (13) 1345-1356
    CrossrefPubMedGoogle Scholar
  • 3 Ruiz-Villaverde R, Blasco-Melguizo J, Hernández-Jurado I, Naranjo-Sintes R, Gutierrez Salmerón MT. Bilateral and multiple periungual fibromas as an oligosymptomatic form of tuberous sclerosis. Dermatology 2004; 209 (02) 160-161
    CrossrefPubMedGoogle Scholar
  • 4 Schwartz RA, Fernández G, Kotulska K, Jóźwiak S. Tuberous sclerosis complex: advances in diagnosis, genetics, and management. J Am Acad Dermatol 2007; 57 (02) 189-202
    CrossrefPubMedGoogle Scholar
  • 5 Green AJ, Smith M, Yates JR. Loss of heterozygosity on chromosome 16p13.3 in hamartomas from tuberous sclerosis patients. Nat Genet 1994; 6 (02) 193-196
    CrossrefPubMedGoogle Scholar
  • 6 Michel J-L, Grognard C, Toubel G, Cartier H, Fusade T, Perrin D. CO2, Er:YAG and pulsed dye laser treatment of angiofibromas in patients with tuberous sclerosis. Med Laser Appl 2004; 19 (03) 136-145
    CrossrefGoogle Scholar
  • 7 Landthaler M, Haina D, Hohenleutner U, Seipp W, Waidelich W, Braun-Falco O. [The CO2 laser in dermatotherapy–use and indications]. [The CO2 laser in dermatotherapy–use and indications] Hautarzt 1988; 39 (04) 198-204
    PubMedGoogle Scholar
  • 8 Fioramonti P, De Santo L, Ruggieri M. et al. CO2/Erbium:YAG/Dye laser combination: an effective and successful treatment for angiofibromas in tuberous sclerosis. [published correction appears in Aesthetic Plast Surg. 2017 Jun;41(3):760] Aesthetic Plast Surg 2014; 38 (01) 192-198
    CrossrefPubMedGoogle Scholar
  • 9 Khatri KA, Ross V, Grevelink JM, Magro CM, Anderson RR. Comparison of erbium:YAG and carbon dioxide lasers in resurfacing of facial rhytides. Arch Dermatol 1999; 135 (04) 391-397
    CrossrefPubMedGoogle Scholar
  • 10 Tanzi EL, Alster TS. Single-pass carbon dioxide versus multiple-pass Er:YAG laser skin resurfacing: a comparison of postoperative wound healing and side-effect rates. Dermatol Surg 2003; 29 (01) 80-84
    PubMedGoogle Scholar
  • 11 Herndon DN. Total Burn Care. 5th ed.. Elsevier; 2018: 648-654
    Google Scholar
  • 12 Bernstein EF. The pulsed-dye laser for treatment of cutaneous conditions. G Ital Dermatol Venereol 2009; 144 (05) 557-572
    PubMedGoogle Scholar
  • 13 Salido-Vallejo R, Ruano J, Garnacho-Saucedo G. et al. Facial Angiofibroma Severity Index (FASI): reliability assessment of a new tool developed to measure severity and responsiveness to therapy in tuberous sclerosis-associated facial angiofibroma. Clin Exp Dermatol 2014; 39 (08) 888-893
    CrossrefPubMedGoogle Scholar
  • 14 Dermatology life quality index. Cardiff University. Accessed April 30, 2023. Available at: https://www.cardiff.ac.uk/medicine/resources/quality-of-life-questionnaires/dermatology-life-quality-index
  • 15 Pasyk KA, Argenta LC. Argon laser surgery of skin lesions in tuberous sclerosis. Ann Plast Surg 1988; 20 (05) 426-433
    CrossrefPubMedGoogle Scholar
  • 16 Dvir E, Hirshowitz B. [Cryosurgery for the facial lesions of tuberous sclerosis]. Harefuah 1979; 97 (9–10): 245-246
    PubMedGoogle Scholar
  • 17 Menon PA. Dermabrasion for the management of angiofibromas in tuberous sclerosis. J Dermatol Surg Oncol 1982; 8 (11) 984-985
    CrossrefPubMedGoogle Scholar
  • 18 Fischer K, Blain B, Zhang F, Richards L, Lineaweaver WC. Treatment of facial angiofibromas of tuberous sclerosis by shave excision and dermabrasion in a dark-skinned patient. Ann Plast Surg 2001; 46 (03) 332-335
    CrossrefPubMedGoogle Scholar
  • 19 Lin Y-T, Yu CL, Tu YK, Chi CC. Efficacy and safety of topical mechanistic target of rapamycin inhibitors for facial angiofibromas in patients with Tuberous Sclerosis Complex: a systematic review and network meta-analysis. Biomedicines 2022; 10 (04) 826
    CrossrefPubMedGoogle Scholar
  • 20 Botsalı A, Çalışkan E, Küçük K, Gahramanov İ, Özkan CK. Treatment of tuberous sclerosis facial angiofibromas with erbiumyttrium aluminium garnet laser and topical sirolimus 0.25%. TURKDERM 2020; 54 (01) 19-21
    CrossrefGoogle Scholar